Posts

Oral GLP-1 Tracker: Foundayo and Wegovy Pill Reach New Heights in Obesity Treatment Market

on

Altimmune’s Next-Gen GLP-1 Curbs Heavy Drinking in Unequivocal Phase 2 alcohol use disorder win

on

Hengrui, Kailera’s GLP‑1 Pill Posts Encouraging Efficacy but High Side Effect Rates in Late‑Stage China Trials

on

Endevica spinout Kalohexis files confidential IPO to advance obesity drug rivaling GLP-1s

on

ADA: AZ’s oral GLP‑1 shows competitive efficacy in phase 2, setting stage for pivotal program

on

ADA 2026: Zealand and Roche pitch amylin agonist petrelintide as best‑in‑class obesity monotherapy

on

ADA: Metsera asset data support Pfizer’s entry point into obesity market

on

Obesity care startup Ilant Health raises $15M Series A for AI‑supported precision‑obesity‑care platform

on

Lilly's triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile

on

Design Therapeutics’ Friedreich’s Ataxia Data and Vincentage’s Obesity Results from China

on

Lilly Highlights Low-Dose Zepbound and Foundayo for Long-Term Weight Loss Maintenance

on

UC Berkeley Startup Develops Jumping Genes Gene Therapy for Sustained GLP-1 Weight Loss

on

NOVI Health's Hybrid Care Model Matches Clinical Trial GLP-1 Weight Loss in Real-World Asian Study

on

Novo Nordisk Launches Discounted Multi-Month Subscription Program for Wegovy via Telehealth Providers

on

Ambrosia Biosciences Raises $100M Series B for Oral GLP-1 Drug Development

on

Novo Nordisk's Triple-G Agonist UBT251 Achieves 19.7% Weight Loss in Phase 2 Trial in China

on

Lilly's Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Diabetes Trial, Comparable to Mounjaro

on

Novo Nordisk's High-Dose Wegovy Receives FDA Approval Under Commissioner's Voucher Program

on

Lilly's Triple-G Retatrutide Achieves 16.8% Weight Loss and A1C Reductions in Phase 3 Type 2 Diabetes Trial

on

Structure Therapeutics Reports Strong Phase 2 ACCESS II Data for Oral GLP-1 Aleniglipron with 16% Weight Loss

on